Histone demethylase
LSDl (KDMlA) belongs to the flavin adenine
dinucleotide (FAD) dependent family of monoamine oxidases and is vital
in regulation of mammalian biology. Dysregulation and overexpression
of LSD1 are hallmarks of a number of human diseases, particularly
cancers that are characterized as morphologically poorly differentiated.
As such, inhibitors of LSD1 have potential to be beneficial as a cancer
therapy. The most clinically advanced inhibitors of LSDl are covalent
inhibitors derived from tranylcypromine (TCP). Herein, we report the
discovery of a novel series of reversible and selective LSDl inhibitors.
Exploration of structure–activity relationships (SARs) and
optimization of ADME properties resulted in the identification of
clinical candidate CC-90011. CC-90011 exhibits potent on-target induction
of cellular differentiation in acute myeloid leukemia (AML) and small
cell lung cancer (SCLC) cell lines, and antitumor efficacy in patient-derived
xenograft (PDX) SCLC models. CC-90011 is currently in phase 2 trials
in patients with first line, extensive stage SCLC (ClinicalTrials.gov
identifier: NCT03850067).
[reaction: see text] The ability of methyl(trifluoromethyl)dioxirane to cleave p-methoxylbenzyl ethers oxidatively in the presence of various additional functional groups has been investigated. These reactions, performed in aqueous acetonitrile, transform a reasonably robust aryl substituent into a dienyl aldehydo ester. The originally generated E,Z-isomer undergoes slow conversion to the more stable E,E-form at 20 degrees C.
We here present an optimized, scalable synthesis of bromodomain and extra-terminal (BET) inhibitor BMS-986378 (CC-90010). The original route and process 1A was 7 steps with 33.8% yield and featured numerous problematic solvents, process safety concerns, difficult to scale unit operations, and challenging to control impurities. Reaction optimization to remove or mitigate these challenges resulted in our first scale-up route and process, 2A. Subsequent challenges encountered on scale-up of route and process 2A warranted the creation and implementation of an enhanced process, which eliminated dichloromethane from a phenol bromination, improved catalyst performance in the penultimate cross-coupling, and finally developed a concomitant solvent charging process for form control in the final API crystallization. The resulting scale-up route and process, 2B, was demonstrated on a >50 kg scale and afforded the final product in 49% yield over 7 steps in >99.9% assay and area purity, meeting all ICH requirements for quality.
Retinoic acid receptor-related orphan nuclear receptor (ROR) γt is a member of the RORC nuclear hormone receptor family of transcription factors. RORγt functions as a critical regulator of thymopoiesis and immune responses. RORγt is expressed in multiple immune cell populations including Th17 cells, where its primary function is regulation of immune responses to bacteria and fungi through IL-17A production. However, excessive IL-17A production has been linked to numerous autoimmune diseases. Moreover, Th17 cells have been shown to elicit both pro- and anti-tumor effects. Thus, modulation of the RORγt/IL-17A axis may represent an attractive therapeutic target for the treatment of autoimmune disorders and some cancers. Herein we report the design, synthesis and characterization of three selective allosteric RORγt inhibitors in preclinical models of inflammation and tumor growth. We demonstrate that these compounds can inhibit Th17 differentiation and maintenance in vitro and Th17-dependent inflammation and associated gene expression in vivo , in a dose-dependent manner. Finally, RORγt inhibitors were shown to inhibit tumor formation in pancreatic ductal adenocarcinoma (PDAC) organoids.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.